Cochrane · systematic review · CD010458

Tafenoquine for preventing relapse in people with Plasmodium vivax malaria

Rodrigo, C, Rajapakse, S, Fernando, D · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library

Infectious Diseases2 versionsAMSTAR 2: not assessed

SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.

Questions

current version

GRADE rated

No studies

Included studies

No studies 0 · 0%Ungraded 0 · 0%Very low 2 · 33.3%Low 0 · 0%Moderate 4 · 66.7%High 0 · 0%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

Current version only

Summary of findings table 1

Population: adults with P vivax malaria

CD010458.PUB3 (current) · 3 questions

Outcome	Effect	Evidence	Status / GRADE
P vivax parasitaemia during 6 months of	RR 0.32 [0.12, 0.88]	2 studies · 504 participants	Moderate Downgraded: risk of bias, imprecision, inconsistency, indirectness
Serious adverse events	RR 1.34 [0.63, 2.84]	2 studies · 504 participants	Very low Downgraded: risk of bias, imprecision, indirectness
Any adverse event	RR 0.96 [0.81, 1.13]	2 studies · 504 participants	Moderate Downgraded: risk of bias, indirectness

Summary of findings table 2

Population: adults and children with P vivax malaria

CD010458.PUB3 (current) · 3 questions

Outcome	Effect	Evidence	Status / GRADE
P vivax parasitaemia during 6 months of	1.04 [0.8, 1.34]	3 studies · 747 participants	Moderate Downgraded: risk of bias, inconsistency, indirectness
Serious adverse events	RR 1.41 [0.7, 2.83]	3 studies · 747 participants	Very low Downgraded: risk of bias, imprecision, indirectness
Any adverse event	RR 1.01 [0.89, 1.14]	3 studies · 747 participants	Moderate Downgraded: risk of bias, indirectness

Summary of findings table 1

Population: Adults and children withP. vivax malaria

CD010458.PUB2 · 2 questions

Outcome	Effect	Evidence	Status / GRADE
Recurrent P. vivax parasitaemia during six months of	RR 0.19 [0.08, 0.41]	1 study · 110 participants	Moderate Downgraded: risk of bias, imprecision, indirectness
Serious adverse events	RR 0.94 [0.34, 2.59]	3 studies · 358 participants	Low Downgraded: imprecision, indirectness

Summary of findings table 2

Population: Adults and children withP. vivax malaria

CD010458.PUB2 · 2 questions

Outcome	Effect	Evidence	Status / GRADE
Recurrent P. vivax parasitaemia during six months of	RR 0.41 [0.15, 1.14]	1 study · 79 participants	Low Downgraded: risk of bias, imprecision, indirectness
Serious adverse events	RR 0.47 [0.2, 1.08]	2 studies · 323 participants	Low Downgraded: imprecision, indirectness